Hypospadias is a common congenital malformation of the male external genitalia. We performed a genome-wide association study using pooled DNA from 436 individuals with hypospadias (cases) and 494 controls of European descent and selected the highest ranked SNPs for individual genotyping in the discovery sample, an additional Dutch sample of 133 cases and their parents, and a Swedish series of 266 cases and 402 controls. Individual genotyping of two SNPs (rs1934179 and rs7063116) in DGKK, encoding diacylglycerol kinase κ, produced compelling evidence for association with hypospadias in the discovery sample (allele-specific odds ratio (OR) = 2.5, P = 2.5 × 10 −11 and OR = 2.3, P = 2.9 × 10 −9 , respectively) and in the Dutch (OR = 3.9, P = 2.4 × 10 −5 and OR = 3.8, P = 3.4 × 10 −5 ) and Swedish (OR = 2.5, P = 2.6 × 10 −8 and OR = 2.2, P = 2.7 × 10 −6 ) replication samples. Expression studies showed expression of DGKK in preputial tissue of cases and controls, which was lower in carriers of the risk allele of rs1934179 (P = 0.047). We propose DGKK as a major risk gene for hypospadias.
Hypotheses about the multifactorial etiology of hypospadias mainly focus on hormonal disturbances. Polymorphisms in endocrinerelated genes have been associated with hypospadias [3] [4] [5] [6] [7] [8] [9] [10] [11] . However, most of these associations have been found in small studies and were not replicated in the series used in the present study 12 . Therefore, our understanding of the molecular pathways leading to hypospadias is incomplete.
With the availability of SNP microarrays, genomewide association studies (GWASs) have become feasible in elucidating the genetic basis of common complex disorders. Large sample sizes are needed in GWASs to detect genetic factors with modest effects on disease risk, having substantial implications in terms of costs. A useful solution is offered by DNA pooling, which has been proven to be feasible and accurate [13] [14] [15] .
To identify genetic variants contributing to hypospadias suscep tibility, we performed the first GWAS for this malformation using pooled DNA samples. We included 436 cases of European descent with isolated anterior or middle hypospadias from the AGORA (Aetiologic research into Genetic and Occupational/environmental Risk factors for Anomalies in children) project (Supplementary Fig. 1 and Supplementary Table 1 ) and 494 unaffected male controls of European descent from the Nijmegen Biomedical Study. In this discovery sample, we allelotyped 906,600 SNPs in duplicate using Affymetrix GeneChip 6.0 microarrays and calculated allele OR, odds ratio; CI, confidence interval.
l e t t e r s frequencies using kcorrected signal intensities (see Supplementary Note). The worst performing 5% of measurements, indicated by the biggest differences between the allele frequency estimates from the duplicate measurements, were excluded. Furthermore, we excluded SNPs based on several quality control criteria, such as high variance in case or control pools and minor allele frequencies (MAF) below 5%. A total of 574,400 SNPs passed quality control steps and were included in the analyses. We selected the 50 highest ranked SNPs based on the standard χ 2 statistic and a modified χ 2 statistic 16 applied to the raw and kcorrected allele frequency estimates. Of these 50 SNPs, we chose 20 based on several criteria, such as location near a gene and MAF (Supplementary Table 2 ). Seven of these 20 SNPs were located in the Xchromosomal gene DGKK, encoding diacylglycerol kinase κ.
As most SNPs in this gene are in strong linkage disequilibrium (LD) with each other (Supplementary Fig. 2 ), we selected the intronic SNP that tagged the most other SNPs (rs1934179) for individual geno typing in the discovery sample, as well as a potentially regulatory SNP in the 5′ upstream region (rs7063116). Furthermore, nine SNPs in other genes were individually genotyped (Supplementary Table 3) . Individual genotyping was completed with a success rate of ≥99%. All genotype frequencies in the controls were in HardyWeinberg equilibrium (P > 0.05). Both SNPs in DGKK showed genomewide significant association in the discovery sample (OR for the A (risk) allele of these Xchromosomal SNPs in our male sample = 2.5, P = 2.5 × 10 −11 for rs1934179 and OR = 2.3, P = 2.9 × 10 −9 for rs7063116) ( Table 1) . These results were validated by genotyping the parents of the cases using the transmission disequilibrium test, a method robust to population stratification ( Table 2) . Eight of the other nine SNPs showed suggestive association with hypospadias (P < 0.05) (Supplementary Table 4) .
For the ten associated SNPs, we subsequently attempted replication in an additional Dutch sample of 133 anterior or middle hypospa dias cases of European descent and their parents. Seven SNPs showed similar ORs in this sample compared to the discovery sample, although most of these SNPs did not reach statistical significance, probably due to the small number of heterozygous parents. The only exceptions to this were the SNPs in DGKK, in which the same A alleles were again strongly associated with hypospadias (OR = 3.9, P = 2.4 × 10 −5 for rs1934179 and OR = 3.8, P = 3.4 × 10 −5 for rs7063116) ( Table 1 and  Supplementary Table 5) . A second replication in a Swedish cohort of 266 anterior or middle hypospadias cases and 402 male controls convincingly confirmed the associations with the A alleles of the SNPs in DGKK (OR = 2.5, P = 2.6 × 10 −8 for rs1934179 and OR = 2.2, P = 2.7 × 10 −6 for rs7063116), whereas associations with the other eight SNPs did not reach statistical significance ( Table 1 and Supplementary  Table 6 ). We then performed a metaanalysis with both the discovery sample and the two replication samples (Supplementary Table 7 ). In addition to the SNPs in DGKK, SNPs in PPARGC1B (rs4705372) and GRID1 (rs1880386) reached statistical significance in this analysis after correcting the critical P value for multiple testing (critical Bonferroni P < 0.005).
The pathogenesis of hypospadias probably includes many causal factors. We calculated the population attributable fraction (PAF) for hypospadias of rs1934179 in DGKK to be 32% in the Dutch popula tion and 31% in the Swedish population, meaning that the variant underlying the association between rs1934179 in DGKK and hypo spadias is one of the causal factors in nearly one third of hypospadias cases. As a comparison, the PAF for APOE in Alzheimer's disease is 26% (ref. 17) , and that association is one of the strongest and best known genetic associations reported for a multifactorial disorder. However, the PAF calculated for hypospadias is based on data from our study only, and independent populationbased studies should be performed to verify the validity of the estimate.
DGKK encodes a human type II diacylglycerol kinase 18 . Diacyl glycerol kinases modulate the balance between diacylglycerol and phosphatidic acid, two signaling lipids, thereby playing an important role in signal transduction. DGKK mRNA is most abundant in testis and placenta 18 . Although DGKK has not previously been associated with hypospadias and there are other genes in close proximity to it, we suggest DGKK as the hypospadias susceptibility gene in the identified Xchromosomal locus as the LD block in which the gene is located encompasses only DGKK (Supplementary Fig. 2 ). Because the LD block also covers likely regulatory regions, variants regulating DGKK expression may underlie the association of DGKK with hypospadias. We performed realtime quantitative PCR analyses showing that DGKK is expressed in preputial skin of all investigated healthy boys (n = 10) and of hypospadias cases (n = 14) (Supplementary Fig. 3 ). Expression was lower in individuals with the A (risk) allele (n = 15) of rs1934179 (P = 0.047) (Fig. 1) . These results suggest that vari ants regulating DGKK mRNA expression underlie the association of rs1934179 with hypospadias. A search for potential functional vari ants identified one SNP in a FOXL1 transcription factor binding site, rs1934176, which is in high LD (r 2 = 0.99) with rs1934179; however, the significance of this SNP requires further study.
SNPs in GRID1, PPARGC1B and KIAA2022 showed associations in the same direction in the discovery sample and in both replica tion samples, resulting in outcomes with a higher level of statistical significance in the metaanalysis. This suggests that nonsignificance of results may be due to lack of power. Indeed, the power of our study to detect associations with OR < 1.5 was limited and was even further reduced by the fact that we used DNA pooling. Using DNA pools instead of individual DNA samples results in less accurate allele fre quency estimates, possibly producing more falsepositive and false negative findings. Validating our results by individual genotyping enabled us to identify falsepositive findings arising from such inac curate estimates. Falsenegative results cannot be identified, however, and we may have missed additional associations that we would have detected with a GWAS based on individual genotyping. In addition, we may have missed associations with rare variants by excluding SNPs with MAF below 5%, that is, SNPs for which we had insufficient power. Therefore, individual GWAS (preferentially in larger samples) may identify additional hypospadias loci. Previously performed studies showed familial occurrence of hypo spadias for anterior and middle forms of hypospadias but not for posterior types 1, 19 . Because of this apparent etiologic heterogeneity, we included only anterior and middle cases in the current analyses. As expected, an additional analysis of the SNPs in DGKK in cases with posterior hypospadias showed weaker associations ( Table 3) , although the small number of cases used may have hampered a fair comparison. Nevertheless, these data are compatible with anterior and middle forms of hypospadias having an oligogenic or polygenic multifactorial etiology, including a crucial role for DGKK, and with posterior forms having a different etiology. These results warrant stratification by hypospadias phenotype based on location of the urethral opening in future genetic studies, which may reduce genetic heterogeneity and improve the reproducibility of the results.
In summary, we have identified a new Xchromosomal risk locus for hypospadias. We showed expression of DGKK in preputial skin, which was lower in boys with the risk allele. We propose DGKK as a major risk gene for anterior and middle forms of hypospadias. Because hypospadias is a fusion defect, DGKK might be important for other congenital closure defects as well.
URLs. http://www.eurocatnetwork.eu/; R, http://www.Rproject. org; Review Manager 5, http://www.ccims.net/revman.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Genome-wide analysis. We allelotyped each pool in duplicate using Affymetrix GeneChip 6.0 microarrays containing 906,600 polymorphic SNPs. Array experiments were performed according to protocols provided by the manufacturer. We used the SNPMaP package 21 in the statistical soft ware program R (see URLs) to calculate relative allele signal (RAS) scores and kcorrected raw allele frequency (RAF k ) estimates for each SNP, as is described in the Supplementary Note. A total of 574,400 SNPs passed quality control steps (described in the Supplementary Note) and were included in the association analyses. We aver aged data across case pools and control pools separately to obtain RAF k and RAS estimates for cases and controls. We subsequently calculated the modified χ 2 statistic 16 , which is expressed as: where P cases is the allele frequency estimate (RAF k ) in the case pools, P controls is the RAF k in the control pools and P p is an estimate of the allele frequency in the population, for which we used the allele frequency in 603 individu ally genotyped healthy inhouse controls of European descent 22 . N cases is the number of individuals in the case pools and N controls is the number of indi viduals in the control pools, taking into account the loss of cases and controls after the quality control. A SNPspecific variance calculated across the two measurements for each DNA pool was averaged across the pools to obtain σ 2 pool . Finally, np cases and np controls are the number of measurements (pools) for the case and control pools. We selected the 5,000 SNPs with the highest z scores and calculated two additional statistics for these SNPs: the standard χ 2 statistic using the expected numbers of alleles in the cases and controls calculated from the RAF k estimates and the adjusted χ 2 statistic using the RAS values. Combining the results from all three statistics enabled us to select the most promising SNPs.
We used several criteria to select SNPs from the pooled GWAS as eligible for individual genotyping in the discovery sample to validate the results as is described in the Supplementary Note. Ultimately, 20 SNPs were eligible. As seven of these 20 SNPs were in high LD within DGKK (Supplementary Fig. 2) , we genotyped the SNP that tagged most of the other SNPs (rs1934179, an intronic SNP). In addition, we genotyped a potentially regulatory SNP in the 5′ upstream region (rs7063116).
Validation of the results from the pooled GWAS. TaqMan SNP genotyping assays could not be designed for four of the 15 SNPs that were selected for indi vidual genotyping in the discovery sample. We excluded these SNPs from fur ther analysis. The other 11 SNPs (Supplementary Table 3) were individually genotyped using 5′ nuclease TaqMan SNP genotyping assays (Supplementary Table 8 ). In each 96well plate, we loaded five wells with randomly selected duplicate DNA samples from the same and other plates for quality control purposes. In addition, we included four blanks in each plate. Genotyping was completed with a success rate of at least 99%.
All genotype frequencies in controls were in HardyWeinberg equilibrium, with P values ranging from 0.34 to 0.94. For the genotyped SNPs, we calculated ORs for hypospadias risk and the corresponding 95% confidence intervals (CIs) at a genotypic and an allelic level using the most frequent homozygous genotypes in controls as reference values. Furthermore, we performed χ 2 tests. When the expected cell numbers were below five, exact 95% CIs around the ORs were calculated using the Fisher exact method. Ten of the associations were statistically significant (P < 0.05), but only the association with the two SNPs in the Xchromosomal DGKK gene reached genomewide significance (P < 5.0 × 10 −8 ) (Supplementary Table 4) . These results were validated by genotyping the parents of the cases. For these caseparent triads, we used the transmission disequilibrium test (TDT) 23 for statistical analysis of the data with the software program Haploview 4.1 (ref. 24) . Furthermore, we calculated the ORs for hypospadias risk and the corresponding 95% CIs at the allelic level 25 ( Table 2) .
Replication studies. A detailed description of the study populations can be found in the Supplementary Note. The ArnhemNijmegen Regional Committee on Research Involving Human Subjects and the Ethics Committee at Karolinska Institutet approved the studies and all participants and/or their parents gave written informed consent for participation in the studies.
For the Dutch replication sample, we genotyped 133 cases of European descent with isolated anterior or middle hypospadias and their parents for the SNPs that were associated with hypospadias in the individually geno typed discovery sample (P < 0.05). Genotyping was completed with a success rate of at least 95%. All genotype frequencies in the parents were in Hardy Weinberg equilibrium (with P values ranging from 0.16 to 0.99). For these caseparent triads, we again used the TDT 23 for statistical analysis of the data with the software program Haploview 4.1 (ref. 24) , and we calculated the ORs for hypospadias risk and the corresponding 95% CIs at the allelic level 25 (Supplementary Table 5 ).
For the Swedish replication sample, we genotyped 266 Swedish cases with anterior or middle hypospadias and 402 male Swedish controls for the SNPs that were associated with hypospadias in the individually genotyped discov ery sample (P < 0.05). Genotyping was completed with a success rate of at least 98%. All genotype frequencies in the controls were in HardyWeinberg equilibrium (with P values ranging from 0.13 to 0.99), except for rs1022357 in SLCO3A1 (P = 0.01). However, after correcting the critical P value for multiple testing, this result did not reach statistical significance (critical Bonferroni P < 0.005). We calculated ORs for hypospadias risk and the corresponding 95% CIs at genotypic and allelic level, performed χ 2 tests and calculated exact 95% CIs around the ORs using the Fisher exact method when expected cell numbers were below five (Supplementary Table 6 ).
Meta-analysis. We combined the results of both the discovery sample and the two replication samples in a metaanalysis in Review Manager 5 (see URLs) using the inversevariance method and random effects models (Supplementary Table 7 ).
Expression of DGKK. We isolated RNA from preputial skin samples from 14 hypospadias cases and ten agematched controls. The origin of the samples and the methods used are described in the Supplementary Note. We performed RTPCR according to the standard protocol as described in the Supplementary Note. Expression levels of DGKK were reported relative to GAPDH. We also genotyped DNA samples for the two SNPs in DGKK and compared relative gene expression levels between boys with the G allele (45.9% of GAPDH, n = 9) and the A (risk) allele (40.1% of GAPDH, n = 15) of the Xchromosomal SNP rs1934179 in DGKK using the independent samples t test.
Search for potential functional variants. We searched different databases, such as dbSNP and HapMap, for nonsynonymous SNPs that might be causa tive variants, taking validation of the SNPs, conservation of amino acids, and Grantham scores of amino acid replacements into account. Concerning non coding areas, we used the UCSC genome browser to check for microRNA binding sites, enrichments of histone marks associated with enhancers or promoters, and for transcription factor binding sites. where OR is the odds ratio and q is the proportion of exposed individuals (proportion of individuals with the risk allele) in the control group, which is the A allele of rs1934179 in DGKK.
